MUC1 carrying core 2 O-glycans functions as a molecular shield against NK cell attack, promoting bladder tumor metastasis - Wikidata - awgldk - TriplyDB

MUC1 carrying core 2 O-glycans functions as a molecular shield against NK cell attack, promoting bladder tumor metastasis

MUC1 carrying core 2 O-glycans functions as a molecular shield against NK cell attack, promoting bladder tumor metastasis

http://www.wikidata.org/entity/Q39374390

about

The Sweet Side of Immune Evasion: Role of Glycans in the Mechanisms of Cancer Progression Mucin-1 Increases Renal TRPV5 Activity In Vitro, and Urinary Level Associates with Calcium Nephrolithiasis in Patients Perturbation of NK cell peripheral homeostasis accelerates prostate carcinoma metastasis.Tumor-released Galectin-3, a soluble inhibitory ligand of human NKp30, plays an important role in tumor escape from NK cell attack Glycan elongation beyond the mucin associated Tn antigen protects tumor cells from immune-mediated killing.Single molecule study of heterotypic interactions between mucins possessing the Tn cancer antigen.Complex of MUC1, CIN85 and Cbl in Colon Cancer Progression and Metastasis.Tumor-Associated Glycans and Immune Surveillance Unlocking Cancer Glycomes from Histopathological Formalin-fixed and Paraffin-embedded (FFPE) Tissue Microdissections.In Vitro Assessment of the Expression and T Cell Immunogenicity of the Tumor-Associated Antigens BORIS, MUC1, hTERT, MAGE-A3 and Sp17 in Uterine Cancer.Usefulness of traditional serum biomarkers for management of breast cancer patients.Recent progress and perspectives on prostate cancer biomarkers.Mucins in pancreatic cancer and its microenvironment.Evolving mechanistic insights into galectin functions.Biosynthetic Machinery Involved in Aberrant Glycosylation: Promising Targets for Developing of Drugs Against Cancer Acceptor specificities and selective inhibition of recombinant human Gal- and GlcNAc-transferases that synthesize core structures 1, 2, 3 and 4 of O-glycans Core2 O-glycan-expressing prostate cancer cells are resistant to NK cell immunity.Interactions of mucins with the Tn or Sialyl Tn cancer antigens including MUC1 are due to GalNAc-GalNAc interactions.Stage Dependence, Cell-Origin Independence, and Prognostic Capacity of Serum Glycan Fucosylation, β1-4 Branching, β1-6 Branching, and α2-6 Sialylation in Cancer.Over forty years of bladder cancer glycobiology: Where do glycans stand facing precision oncology?Galectins and Carcinogenesis: Their Role in Head and Neck Carcinomas and Thyroid Carcinomas.Altered Proteome of Extracellular Vesicles Derived from Bladder Cancer Patients Urine.Anti-CTLA-4 based therapy elicits humoral immunity to galectin-3 in patients with metastatic melanoma.Extracellular Vesicles in Bladder Cancer: Biomarkers and Beyond

P2860

Q26750877-904D48E0-1C4B-4B6F-B26E-A130AAA53757 Q30386353-9640ABF2-AC56-46F9-A245-BF5E17A2DC61 Q30547087-27BDD243-C1AC-4721-9056-0FB8AC907402 Q34580297-F9F349CC-0722-4B38-A053-1F42FE59D7BB Q34988382-C3054656-CB4A-409C-B0E1-FE4CD4E78156 Q35216220-D8416D3E-3097-4769-88E3-0D9FBCF3E12C Q35237521-391BDCD5-4AB6-4400-82DF-B5276841A253 Q35890610-30C812EE-DCB8-4214-8E5B-E290548D6810 Q36260470-0299F6FD-5809-4A6D-925B-629ACE8AFF30 Q37286552-B56979BA-65CD-49E9-B586-8B6E0C06B992 Q37375636-16022AC4-7306-4790-A1A1-9E4D31C29C9B Q37736079-2003FA5A-000A-4D7A-B61B-C2AEEC1330C3 Q38121746-D6F7C152-098D-49B3-A644-FC8F2D7B5686 Q38254055-8997B6BB-647D-4FA9-9EB7-9DF71680C58E Q38544783-AAB3686C-9CFA-4064-A330-7617A69C470D Q39010258-201D2E64-0677-4FCD-9A5E-62CC606703BC Q39242218-5EB7539E-D03C-4779-B3AD-E237971A9336 Q39696121-664E8CE6-C15E-4562-98E9-996E0D32655E Q45072735-56965875-FB15-461F-A6E1-84F03CC51CDD Q47281580-F626CA3D-29A3-426F-91B8-6F01C98255D6 Q47438594-9283D8C8-6A1D-4401-B6C9-665F1315D7E8 Q55020802-9A20F551-70CF-41F6-80F4-240350513867 Q55119445-38953F68-1DF8-4F71-84D4-CD7E1CD5D430 Q58722406-A29AA3E3-21CA-4497-A63B-721802F5F88D

P2860

MUC1 carrying core 2 O-glycans functions as a molecular shield against NK cell attack, promoting bladder tumor metastasis

http://www.wikidata.org/entity/Q39374390

description

2012 nî lūn-bûn

@nan

2012年の論文

@ja

2012年学术文章

@wuu

2012年学术文章

@zh-cn

2012年学术文章

@zh-hans

2012年学术文章

@zh-my

2012年学术文章

@zh-sg

2012年學術文章

@yue

2012年學術文章

@zh

2012年學術文章

@zh-hant

name

MUC1 carrying core 2 O-glycans ...... oting bladder tumor metastasis

@en

MUC1 carrying core 2 O-glycans ...... ting bladder tumor metastasis.

@nl

type

label

MUC1 carrying core 2 O-glycans ...... oting bladder tumor metastasis

@en

MUC1 carrying core 2 O-glycans ...... ting bladder tumor metastasis.

@nl

prefLabel

MUC1 carrying core 2 O-glycans ...... oting bladder tumor metastasis

@en

MUC1 carrying core 2 O-glycans ...... ting bladder tumor metastasis.

@nl

P1433

Q39374390-F61905CF-E8DB-494D-A3BE-0293C908BE8B

P1476

Q39374390-3FB4DF06-0D5E-461F-882D-7C1F97D34572

P2093

Q39374390-03EEE4EB-D294-4896-98FF-88BBD9071AF8

Q39374390-0CBEF587-C624-48B6-9791-F3AE86CEC4AC

Q39374390-1313EFE0-AC3B-4812-A4F7-031A98AC29DC

Q39374390-1B6A048C-6E3F-4CB9-A81F-7F46AFCAC5AD

Q39374390-236BEF48-983E-4DC5-88A3-7C2F5DEBFAF2

Q39374390-2C6E71B4-F209-4A76-A45D-133A7A09579B

Q39374390-5DBDA82C-E62A-42AF-9D46-5AD5BB7A5CC7

Q39374390-7217A133-5CB5-4CE3-818F-A19100A29022

Q39374390-768A2023-78D4-434E-884A-598A140F7ED4

Q39374390-93F7002B-2EC6-4640-A89C-A63B42FE0622

P2860

Q39374390-0158EEA4-A5ED-4420-86F5-B2B21337125D

Q39374390-09B40513-26DB-440F-9532-006C580D29F5

Q39374390-137C85ED-35CA-4DDB-8BA7-136E7F12F76A

Q39374390-25BCF791-6974-460A-8C82-5D0E1FCEEE4F

Q39374390-3EDECF4D-09C9-460B-9FCF-2A977D69D9EB

Q39374390-567B8DA6-DD6A-4CD8-AA16-30E92EEB2DAF

Q39374390-568D479F-BC85-4CAF-B30A-5AC2C1347C49

Q39374390-666B0834-62CD-4F13-9A63-F87C6E8DCDB1

Q39374390-6688FD65-F69E-49B3-8937-DF3CC0E6F756

Q39374390-7A3FCBED-54A6-4419-A1D0-D3C1CF2EF33B

P304

Q39374390-7FB2DEDE-BFE0-438C-9605-340E48C06A0F

P31

Q39374390-7D86AE8F-EEFC-4608-ACD5-D126DE002F90

P356

Q39374390-4DD0E37F-6143-4FEB-A785-D6B40D0E2476

P433

Q39374390-FDCBDABF-ABF3-4893-A005-D7D05B6BE449

P478

Q39374390-378A71AF-BAE3-48E4-9987-6CB99CE8FF94

P577

Q39374390-A7656D69-D7F2-4236-9FF4-EEF7033F0619

P5875

Q39374390-6D79356A-4AD5-459C-B7E5-F407BFE37202

P698

Q39374390-0A20DB9F-B954-4438-BDA3-AC60AD873BDA

P932

Q39374390-DF625105-B720-4057-8CCC-0E2ABA6C0A7E

P356

P1433

International Journal of Oncology

P1476

MUC1 carrying core 2 O-glycans ...... oting bladder tumor metastasis

@en

P2093

Chikara Ohyama

http://www.w3.org/2001/XMLSchema#string

Hayato Yamamoto

http://www.w3.org/2001/XMLSchema#string

Hisao Saitoh

http://www.w3.org/2001/XMLSchema#string

Kanemitsu Yamaya

http://www.w3.org/2001/XMLSchema#string

Kazuyuki Mori

http://www.w3.org/2001/XMLSchema#string

Mihoko Sutoh

http://www.w3.org/2001/XMLSchema#string

Minoru Fukuda

http://www.w3.org/2001/XMLSchema#string

Shigeru Tsuboi

http://www.w3.org/2001/XMLSchema#string

Shingo Hatakeyama

http://www.w3.org/2001/XMLSchema#string

Takuya Koie

http://www.w3.org/2001/XMLSchema#string

P2860

A novel strategy for evasion of NK cell immunity by tumours expressing core2 O-glycans

Episialin (MUC1) overexpression inhibits integrin-mediated cell adhesion to extracellular matrix components

Association of cell surface mucins with galectin-3 contributes to the ocular surface epithelial barrier

Mucins in cancer: protection and control of the cell surface

Altered Golgi localization of core 2 beta-1,6-N-acetylglucosaminyltransferase leads to decreased synthesis of branched O-glycans

Expression of core 2 beta1,6-N-acetylglucosaminyltransferase facilitates prostate cancer progression

Galectins: structure, function and therapeutic potential

Cancer metastasis: building a framework

Up on the tightrope: natural killer cell activation and inhibition

Death-receptor O-glycosylation controls tumor-cell sensitivity to the proapoptotic ligand Apo2L/TRAIL.

P304

1831-1838

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.3892/IJO.2012.1411

http://www.w3.org/2001/XMLSchema#string

P433

6

http://www.w3.org/2001/XMLSchema#string

P478

40

http://www.w3.org/2001/XMLSchema#string

P577

2012-03-23T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

221975316

http://www.w3.org/2001/XMLSchema#string

P698

22446589

http://www.w3.org/2001/XMLSchema#string

P932

3396290

http://www.w3.org/2001/XMLSchema#string